219 related articles for article (PubMed ID: 24015339)
21. A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil.
Zwicke DL; Restrepo-Jaramillo R; Alnuaimat H; Gordon K; Broderick M; Edwards LD; Allmon A; Leary PJ
Pulm Circ; 2021; 11(1):2045894021998203. PubMed ID: 33738096
[TBL] [Abstract][Full Text] [Related]
22. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
[No Abstract] [Full Text] [Related]
23. Prostanoids for pulmonary arterial hypertension.
Galiè N; Manes A; Branzi A
Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
25. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
26. Inhaled iloprost for the control of pulmonary hypertension.
Krug S; Sablotzki A; Hammerschmidt S; Wirtz H; Seyfarth HJ
Vasc Health Risk Manag; 2009; 5(1):465-74. PubMed ID: 19475782
[TBL] [Abstract][Full Text] [Related]
27. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
28. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
Osvaldo Cáneva J; Ossés JM
Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
[TBL] [Abstract][Full Text] [Related]
29. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
[TBL] [Abstract][Full Text] [Related]
30. Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension.
Yildiz M; Kahraman S; Surgit O; Zencirkiran Agus H; Uygur B; Demir AR; Kalkan ME; Memic Sancar K; Oner E; Gurbak İ; Kalkan AK
Herz; 2022 Apr; 47(2):158-165. PubMed ID: 34114047
[TBL] [Abstract][Full Text] [Related]
31. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
Smith ZR; Kelly B; Awdish RL; Hegab S
J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
Waxman AB; Zamanian RT
Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
[TBL] [Abstract][Full Text] [Related]
33. Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns.
Yıldırım Ş
Pulm Circ; 2023 Jul; 13(3):e12268. PubMed ID: 37469523
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
35. Long-term treatment of pulmonary hypertension with aerosolized iloprost.
Machherndl S; Kneussl M; Baumgartner H; Schneider B; Petkov V; Schenk P; Lang IM
Eur Respir J; 2001 Jan; 17(1):8-13. PubMed ID: 11307761
[TBL] [Abstract][Full Text] [Related]
36. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbruck B; Grimminger F; Seeger W
Am J Respir Crit Care Med; 1999 Aug; 160(2):600-7. PubMed ID: 10430735
[TBL] [Abstract][Full Text] [Related]
37. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension.
Hoeper MM; Spiekerkoetter E; Westerkamp V; Gatzke R; Fabel H
Eur Respir J; 2002 Aug; 20(2):339-43. PubMed ID: 12212965
[TBL] [Abstract][Full Text] [Related]
38. Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.
Hinkamp C; Bartolome S; Mims E; Chin K; Shah T
Biomed Hub; 2022; 7(3):115-124. PubMed ID: 36465803
[TBL] [Abstract][Full Text] [Related]
39. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost.
Olschewski H; Ghofrani HA; Walmrath D; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Intensive Care Med; 1998 Jun; 24(6):631-4. PubMed ID: 9681789
[TBL] [Abstract][Full Text] [Related]
40. Inhaled prostanoids in the therapy of pulmonary hypertension.
Gessler T; Seeger W; Schmehl T
J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):1-12. PubMed ID: 18518827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
